According to Research by SNS Insider, U.S. Multiple Myeloma Market is projected to reach USD 13.91 Billion by 2032, as novel drug classes, immunotherapies, and diagnostic advances reshape treatment ...

Researchers sought to determine whether subcutaneous isatuximab would be effective for patients with newly diagnosed MM who are ineligible for transplantation.

A comprehensive US analysis showed that progress in multiple myeloma survival has not been shared equally, with significant disparities persisting despite improved therapies.

Novel drug regimens, autologous stem cell transplant (ASCT), and modern supportive care are prolonging remission, improving ...

Multiple myeloma is predominantly a disease of the elderly, with the median age at diagnosis about 70; one-third of patients are older than 75, and 10% are older than 80. Along with this worldwide ...

Multiple myeloma is relatively rare; in the U.S., the lifetime risk of getting this type of cancer is 1 in 143, and the disease causes less than 13,000 deaths each year, according to the American ...

Improved progression-free survival in multiple myeloma patients following three-drug therapy with autologous stem cell transplant DETERMINATION Trial clarifies benefits and risks of treatment ...

Survival of patients with multiple myeloma (MM), including those who are high-risk or elderly, has continued to improve, according to an abstract presented at the 2019 annual meeting of the ...

The ASPIRE (C A rfilzomib, Lenalidomide, and Dexametha S one versus Lenalidomide and Dexamethasone for the treatment of P at I ents with R elapsed Multiple My E loma) trial achieved its primary ...

Researchers have found that multiple myeloma patients with a genetic variation in the gene FOPNL die on average 1-3 years sooner than patients without it. The finding was identified with a genetic ...

Nearly 20% of patients with multiple myeloma have a form in which they make extreme quantities of one component of the abnormal antibody they are producing, and these so-called “free monoclonal ...

Celine Vachon et al. Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. Nature Communications, July 2015 DOI: 10.1038/ncomms8539 ...